Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib
Journal
Journal of Clinical Oncology
Journal Volume
31
Journal Issue
20
Pages
e335-337
Date Issued
2013
Author(s)
Other Subjects
cefalexin; desoximetasone; doxycycline; epidermal growth factor receptor; ficlatuzumab; fluocinonide; fusidic acid; gefitinib; griseofulvin; protein kinase B; STAT3 protein; antineoplastic agent; ficlatuzumab; gefitinib; monoclonal antibody; quinazoline derivative; aged; alopecia; article; bacterium culture; bone metastasis; case report; controlled study; dermis; disease duration; disease severity; drug withdrawal; enzyme phosphorylation; erythema; face; female; folliculitis; giant cell; hair follicle; hair loss; hair root; histiocyte; human; immunohistochemistry; lung non small cell cancer; lymphocytic infiltration; papule; paronychia; priority journal; protein phosphorylation; punch biopsy; pustule; rash; Retrovirus; scalp; scalp hair; scar formation; sebaceous gland; skin biopsy; skin defect; skin fibrosis; Staphylococcus aureus; T cell lymphoma; treatment duration; trunk; alopecia; bone tumor; chemically induced disorder; follow up; lung non small cell cancer; lung tumor; metastasis; needle biopsy; pathology; risk assessment; scar; severity of illness index; Aged; Alopecia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cicatrix; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Risk Assessment; Severity of Illness Index
Type
journal article